

UNSILENCE AN EXPRESSIVE INSTRUMENT

TAZVERIK[®] (tazemetostat) demonstrated meaningful and sustained responses for relapsed or refractory (R/R) follicular lymphoma (FL) patients, in both MT and WT *EZH2* populations¹



Tazemetostat (TAZVERIK[®]) is included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) for B-cell Lymphomas with a category 2A recommendation as an option for appropriate patients with R/R FL.*

*Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) for B-cell Lymphomas V.4.2021. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed May 10, 2021. To view the most recent and complete version of the guideline, go online to [NCCN.org](https://www.nccn.org). NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

TAZVERIK is indicated for the treatment of:

- Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an *EZH2* mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies.
- Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.

These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).¹

MT=mutant type; WT=wild type; *EZH2*=enhancer of zeste homologue 2.

Please see additional Important Safety Information on the following pages and refer to the full Prescribing Information.


Important Safety Information

TAZVERIK increases the risk of developing secondary malignancies, including T-cell lymphoblastic lymphoma, myelodysplastic syndrome, and acute myeloid leukemia. Monitor patients long-term for the development of secondary malignancies.

TAZVERIK can cause fetal harm. Advise patients of potential risk to a fetus and to use effective non-hormonal contraception.

The most common ($\geq 20\%$) adverse reactions are fatigue, upper respiratory tract infection, musculoskeletal pain, nausea, and abdominal pain.

TAZVERIK® (tazemetostat) DEMONSTRATED EFFICACY IN A HEAVILY PRETREATED POPULATION REGARDLESS OF EZH2 MUTATION STATUS^{1,2*†}



The ORR included **12%** (n=5/42) of patients with a **complete response** and **57%** (n=24/42) with a **partial response**.^{1,2}

**69%
ORR**
(n=29/42; 95%
CI: 53%–82%)^{1,9†}

**10.9
months
median DOR**

Sustained response^{1,2*}
(range: 0.0+ to 22.1+; 95% CI: 7.2–NE)
The data for this cohort were not yet mature at the time of assessment.

ORR=overall response; CI=confidence interval; DOR=duration of response; NE=not estimable.

*TAZVERIK was studied in an open-label, single-arm, multicenter, phase 2 trial with 6 cohorts of patients, including 2 cohorts with histologically-confirmed R/R FL. Patients received 800 mg of TAZVERIK orally twice daily until confirmed disease progression or unacceptable toxicity. The major efficacy outcome measures were ORR and DOR according to the International Working Group Non-Hodgkin Lymphoma (IWG-NHL) criteria as assessed by independent review committee.^{1,2}

†The median number of lines of prior systemic therapy in patients: 2 (range 1 to 11) MT EZH2 and 3 (range 1 to 8) WT EZH2; patients refractory to rituximab: 49% MT EZH2 and 59% WT EZH2; patients double refractory to rituximab and an alkylating agent: 20% MT EZH2 and 28% WT EZH2; patients refractory to their last therapy: 49% MT EZH2 and 41% WT EZH2; patients that had received prior stem cell transplant: 9% MT EZH2 and 39% WT EZH2.^{1,2}

‡The tumor size was measured based on the maximum reduction in the sum of the products of the perpendicular diameters.

Important Safety Information (continued)


Warnings and Precautions

• Secondary Malignancies

The risk of developing secondary malignancies is increased following treatment with TAZVERIK. Across clinical trials of 729 adults who received TAZVERIK 800 mg twice daily, myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) occurred in 0.7% of patients. One pediatric patient developed T-cell lymphoblastic lymphoma (T-LBL). Monitor patients long-term for the development of secondary malignancies.

Please see additional Important Safety Information on the following pages and refer to the full Prescribing Information.

TAZVERIK® (tazemetostat) DEMONSTRATED EFFICACY IN A HEAVILY PRETREATED POPULATION REGARDLESS OF EZH2 MUTATION STATUS^{1,2*†}



The ORR included **4%** (n=2/53) of patients with a **complete response** and **30%** (n=16/53) with a **partial response**.^{1,2}

**34%
ORR**
(n=18/53; 95%
CI: 22%–48%)^{1,9†}

**13.0
months
median DOR**

Sustained response^{1,2*}
(range: 1.0 to 22.5+; 95% CI: 5.6–NE)

‡The tumor size was measured based on the maximum reduction in the sum of the products of the perpendicular diameters. Tumor response was unevaluable in 5 out of 53 WT EZH2 patients in the intent-to-treat population.

Important Safety Information (continued)

Warnings and Precautions

• Embryo-Fetal Toxicity

Based on findings from animal studies and its mechanism of action, TAZVERIK can cause fetal harm when administered to pregnant women. There are no available data on TAZVERIK use in pregnant women to inform the drug-associated risk. Administration of tazemetostat to pregnant rats and rabbits during organogenesis resulted in dose-dependent increases in skeletal developmental abnormalities in both species beginning at maternal exposures approximately 1.5 times the adult human exposure (area under the plasma concentration time curve [AUC_{0-45h}]) at the 800 mg twice daily dose.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TAZVERIK and for 6 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with TAZVERIK and for 3 months after the final dose.

Please see additional Important Safety Information on the following pages and refer to the full Prescribing Information.

TAZVERIK
(tazemetostat) tablets
200 mg

MAJORITY OF PATIENTS WERE ABLE TO STAY ON THE FULL DOSE OF TAZVERIK DURING THE TRIAL¹


- Grade 3 or 4 adverse reactions occurred in ≤5% of patients which included fatigue (5%)*, urinary tract infection (2%)[†], nausea (1%), abdominal pain (3%)[‡], vomiting (1%), and musculoskeletal pain (1%)[§]



of patients **permanently discontinued** treatment due to an adverse reaction. The adverse reaction resulting in permanent discontinuation in ≥2% of patients was second primary malignancy.¹



of patients receiving TAZVERIK required **dose reductions** due to an adverse reaction.¹



of patients receiving TAZVERIK required **dose interruptions** due to an adverse reaction. Adverse reactions requiring dosage interruptions in ≥3% of patients were thrombocytopenia and fatigue.¹

*Includes fatigue and asthenia.

[†]Includes cystitis, urinary tract infection, urinary tract infection staphylococcal.

[‡]Includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper.

[§]Includes back pain, limb discomfort, musculoskeletal chest pain, musculoskeletal discomfort, musculoskeletal pain, myalgia, neck pain, non-cardiac chest pain, pain in extremity, pain in jaw, spinal pain.

Important Safety Information (continued)

Adverse Reactions

In 99 clinical study patients with relapsed or refractory follicular lymphoma receiving TAZVERIK 800 mg twice daily: Serious adverse reactions occurred in 30% of patients who received TAZVERIK. Serious adverse reactions occurring in ≥2% were general physical health deterioration, abdominal pain, pneumonia, sepsis, and anemia. The most common (≥20%) adverse reactions were fatigue (36%), upper respiratory tract infection (30%), musculoskeletal pain (22%), nausea (24%), and abdominal pain (20%).

Drug Interactions

Avoid coadministration of strong or moderate CYP3A inhibitors with TAZVERIK. If coadministration of moderate CYP3A inhibitors cannot be avoided, reduce TAZVERIK dose.

Avoid coadministration of moderate and strong CYP3A inducers with TAZVERIK, which may decrease the efficacy of TAZVERIK.

Coadministration of TAZVERIK with CYP3A substrates, including hormonal contraceptives, can result in decreased concentrations and reduced efficacy of CYP3A substrates.

Lactation

Because of the potential risk for serious adverse reactions from TAZVERIK in the breastfed child, advise women not to breastfeed during treatment with TAZVERIK and for one week after the final dose.

References: 1. TAZVERIK (tazemetostat) Prescribing Information. Cambridge, MA: Epizyme, Inc., July 2020. 2. Data on file. 3. Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. *Lancet Oncol.* 2020;21(11):1433-1442.

Please see additional Important Safety Information throughout this piece and refer to the full Prescribing Information.



**TO LEARN MORE, VISIT
EXPLORETAZVERIK.COM**



© 2021 Epizyme, Inc. All Rights Reserved. TZ-FL-BR-21-0057 08/2021

